BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a
BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a
BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and
BroadOak is pleased to announce its investment in Biolog, a leading provider of cell-based microbial identification
BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract
BroadOak increased its investment in Genomenon, a company that organizes the world’s genomic data. The full
BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and
Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner
BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric
BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI).
It is an exciting time at BroadOak as we help advance innovative life sciences technologies.
Holly Atallah
Director of Finance & Operations
BroadOak has advised and invested in life sciences companies for over 15 years. Get to know us.